Yocon Biotech's GMP Drug Regulation Training Progresses Smoothly, Raising the Bar for Compliant Production

In 2024, with the rapid development of the global pharmaceutical industry and increasingly stringent regulatory requirements, ensuring the quality and safety of drug production has become a core issue that pharmaceutical companies cannot afford to overlook. Cells, as biopharmaceuticals with significant biological activity, are subject to extremely strict regulatory processes.

As a R&D supplier of serum-free culture reagents in the field of cell therapy, Yocon Biotech is well aware that cell therapy pharmaceutical companies are regulated by the GMP rules of the pharmaceutical industry. Therefore, these companies need to hold themselves to the GMP regulations of the pharmaceutical industry during the application and production of cell therapy drugs. Moreover, they also hope that their raw material suppliers will produce raw materials according to the same strict standards (GMP production specifications) and ensure a stable supply chain.

Against this background, Yocon Biotech, in collaboration with SGS, an internationally recognized testing, inspection and certification body, successfully held a special training session on China's GMP (Good Manufacturing Practice) drug regulations. This training not only demonstrates Yocon Biotech's high attention to GMP-compliant production, but also marks a solid step forward for Yocon in enhancing product quality and safety.

As an internationally recognized testing, inspection and certification body, SGS enjoys a high reputation worldwide for its profound professional knowledge, rich industry experience and internationally recognized testing standards. In this cooperation with Yocon Biotech, SGS dispatched a team of senior experts. Through in-depth and easy-to-understand explanations and vivid case analyses, they provided all the employees of Yocon Biotech with a rich and targeted feast of GMP regulation knowledge.

The training content covered the basic concepts, development history, core principles of GMP regulations, as well as their specific applications and practices in the Chinese pharmaceutical industry. The experts elaborated on the latest GMP regulatory requirements, including several key aspects such as production environment control, material management, production process control, quality control and assurance, and personnel training and hygiene. The aim was to help employees deeply understand the essence of GMP regulations and ensure that every link from product R&D to production strictly complies with regulatory requirements, thus guaranteeing the safety and effectiveness of products.

Although Yocon Biotech has always been committed to complying with GMP regulations and has established a complete quality management system and strict production operation procedures, this training is still regarded as a necessary "recharge" and "upgrade". Through the training, the employees of Yocon Biotech not only consolidated their existing GMP knowledge, but also learned about the latest regulatory developments and best practices, further enhancing their compliance awareness and risk prevention and control capabilities.

In the future, Yocon Biotech will continue to strengthen cooperation and exchanges with domestic and foreign authoritative institutions, continuously deepen its study of GMP knowledge, strictly control product quality, and provide customers with safer products with better quality and performance.